<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2007/92196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Serum TNF-Alpha Level Predicts Nonproliferative Diabetic Retinopathy in Children</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zorena</surname><given-names>Katarzyna</given-names></name><xref rid="a1" ref-type="aff"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>My&#x0015b;liwska</surname><given-names>Jolanta</given-names></name><xref rid="a1" ref-type="aff"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>My&#x0015b;liwiec</surname><given-names>Ma&#x00142;gorzata</given-names></name><xref rid="a2" ref-type="aff"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Balcerska</surname><given-names>Anna</given-names></name><xref rid="a2" ref-type="aff"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hak</surname><given-names>&#x00141;ukasz</given-names></name><xref rid="a1" ref-type="aff"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lipowski</surname><given-names>Pawe&#x00142;</given-names></name><xref rid="a3" ref-type="aff"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Raczy&#x00144;ska</surname><given-names>Krystyna</given-names></name><xref rid="a3" ref-type="aff"><sup>3</sup></xref></contrib></contrib-group><aff id="a1"><sup>1</sup>Department of Immunology, Medical University of Gda&#x00144;sk, D&#x00119;binki 1, 80-210 Gda&#x00144;sk, Poland</aff><aff id="a2"><sup>2</sup>Diabetological Department, Clinic of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gda&#x00144;sk, 80-210 Gda&#x00144;sk, Poland</aff><aff id="a3"><sup>3</sup>Department and Clinic of Ophthalmology, Medical University of Gda&#x00144;sk, 80-210 Gda&#x00144;sk, Poland</aff><author-notes><corresp id="cor1">*Katarzyna Zorena: <email>kzorena@amg.gda.pl</email></corresp></author-notes><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>17</day><month>5</month><year>2007</year></pub-date><volume>2007</volume><elocation-id>92196</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2006</year></date><date date-type="rev-recd"><day>28</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>1</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Katarzyna Zorena et al.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>The aim of this study was identification of the immunologic markers of the damage to the eye apparatus at early stages of diabetes mellitus (DM) type 1 children. One hundred and eleven children with DM type 1 were divided into two groups: those with nonproliferative diabetic retinopathy (NPDR) and without retinopathy. All the children had their daily urine albumin excretion, HbA1c, C-peptide measured, 24-hour blood pressure monitoring, and ophthalmologic examination. Levels of TNF-<italic>&#x003b1;</italic>, IL-6, and IL-12 in serum were measured by ELISA tests (Quantikine High Sensitivity Human by R&#x00026;D Systems, Minneapolis, Minn, USA). The NPDR children demonstrated a significantly longer duration of the disease in addition to higher HbA1c, albumin excretion rate, C-reactive protein, systolic blood pressure, as well as TNF-<italic>&#x003b1;</italic> and IL-6 levels than those without retinopathy. The logistic regression revealed that the risk of NPDR was strongly dependent on TNF-<italic>&#x003b1;</italic> [(OR 4.01; 95%CI 2.01&#x02212;7.96)]. TNF-<italic>&#x003b1;</italic> appears to be the most significant predictor among the analyzed parameters of damage to the eye apparatus. The early introduction of the TNF-<italic>&#x003b1;</italic> antagonists to the treatment of young patients with DM type 1 who show high serum activity of the TNF-<italic>&#x003b1;</italic> may prevent them from development of diabetic retinopathy.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Diabetic retinopathy usually does not occur during the first five years from the diagnosis of diabetes mellitus (DM) type 1, whilst after 10 years of diabetes it is present in over 50% of patients, being the most common cause of loss of vision [<xref ref-type="bibr" rid="B1">1</xref>]. Regardless numerous studies carried out worldwide, daily urine albumin secretion remains to be standard marker of nephropathy development, while ophthalmologic examination stands for diagnosis of retinopathy [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Presently, there is no satisfactory pharmacologic therapy and laser therapy remains to be the leading treatment option in management of DM1 retinopathy in children. Yet still the therapy is aimed at limiting the damage and not at preventing it [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>]. Early detection of the individual tendency for development of diabetic retinopathy, especially before evident changes become visible at the fundus of the eye, is extremely significant in children and adolescent with DM type 1. Most of the published works focus on the role of cytokines in the development of proliferative retinopathy in adults, thus such analysis is limited to the late stages of the retinopathy [<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>]. It has been suggested that hyperglycemia may lead to the activation of proinflammatory cytokines that are crucial for development and progression of retinopathy [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. One of the glucose toxic mechanisms, the protein glycation, is associated with cytokines: tumor necrosis factor-alpha (TNF-<italic>&#x003b1;</italic>), interleukin-6 (IL-6), and interleukin-12 (IL-12) that are substantial factors in the development of diabetic microangiopathy [<xref ref-type="bibr" rid="B9">9</xref>&#x02013;<xref ref-type="bibr" rid="B11">11</xref>]. TNF-<italic>&#x003b1;</italic> and IL-6 may act as local intensification signals in pathological processes associated with chronic eye inflammation [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>]. It has been shown in NOD-mice that also IL-12 is associated with rapid diabetes development [<xref ref-type="bibr" rid="B12">12</xref>]. Therefore, the purpose of this work was the identification of the early immunologic markers of the damage to the eye apparatus in diabetic children.</p></sec><sec sec-type="section" id="sec2"><title>2. PATIENTS AND METHODS</title><p>One hundred and eleven children (age 15 &#x000b1; 2 years) with DM type 1 were recruited from The Diabetological Department, Clinic of Pediatrics, Hematology, Oncology and Endocrinology Medical University of Gda&#x00144;sk. Type 1 DM, was defined in accordance with the criteria of the American Diabetes Association [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec sec-type="section" id="sec3"><title>3. LABORATORY EXAMINATIONS</title><p>HbA1c was measured by an immunoturbidometric method using Unimate 3 set (Hoffmann-La Roche AG, Germany) with a normal range of values 3.0&#x02013;6.0%. Fasting glucose was measured by enzymatic test (Roche Diagnostics GmbH, Germany). Level of CRP was measured with immunochemical system (Beckman Instr. Inc., Ireland). Level of C-peptide was below 0.5ng/ml in all children with type 1 DM. The systolic and diastolic blood pressures were measured using automatic 24-hour ambulatory blood pressure monitoring (ABPM) and all the average values of the blood pressure were expressed in the centile charts. The urinary albumin excretion was expressed as the average of the three 24-hour collections obtained during 6 months prior to the enrolment into the study. Classified as microalbuminuria were the cases when at least in two out of three urine samples albumin excretion was between 30&#x02013;299 mg/24 hours. The urinary albumin excretion is measured by immunoturbidometric assay using Tina-quant (Boehringer Mannheim GmbH, Germany). Serum level of creatinine was measured using CREA assay system (Boehringer Mannheim GmbH, Germany). All patients with type 1 DM required insulin treatment (0.87 &#x000b1; 0.24 U/kg of the body weight).</p></sec><sec sec-type="section" id="sec4"><title>4. OPHTHALMOLOGIC EXAMINATION</title><p>In all children with type 1 DM the ophthalmologic investigation was performed. This included visual acuity tests, intraocular pressure, and anterior segment estimation done by slit lamp (TOPCON SL-82, Japan). The fundus examination was done after installation of 1% Tropicamid to obtain sufficient mydriasis. The examination was performed by using the +90D lens (Ocular Instruments Inc., Bellevue, Wash, USA). Digital camera (Topcon IMAGEnet 2000 Japan) was used to perform the fluorescein angiography.</p><p>The analysis of the eye fundus pictures was based on The International Diabetic Retinopathy Division: 1) nonproliferative retinopathy with or without maculopathy, 2) preproliferative retinopathy, 3) proliferative retinopathy [<xref ref-type="bibr" rid="B15">15</xref>]. According to the ophthalmological examination, the diabetic children were divided into 2 groups: with diabetic retinopathy (21 children) and without retinopathy (90 children). In 21 cases, typical symptoms of nonproliferative diabetic retinopathy were proven. Additionally, 16 children of the group with nonproliferative diabetic retinopathy had microalbuminuria and 7 children were presented with arterial hypertension, while none of the children without retinopathy presented clinical signs of diabetic nephropathy such as microalbuminuria or arterial hypertension.</p><p>A group of 41 healthy children (age 14 &#x000b1; 2 years) volunteered as the control group. They were apparently healthy as based on their medical examination. Written, informed consent was obtained from all children (or from their parents) participating in the study. This study was approved by The Ethics Committee of The Medical University of Gda&#x00144;sk NKEBN/610/2003/2004 and the investigation was carried out in accordance with the principles of the Declaration of Helsinki as revised in 1996.</p></sec><sec sec-type="section" id="sec5"><title>5. SAMPLE COLLECTION</title><p>Plasma samples were collected from the 152 children. Blood samples were immediately placed on ice, clarified by centrifugation at 3.000 &#x000d7; <italic>g</italic> for 5 minutes at 4&#x000b0;C, and kept frozen at &#x02212;80&#x000b0;C until assay.</p></sec><sec sec-type="section" id="sec6"><title>6. DETERMINATION OF TNF-<italic>&#x003b1;</italic>, IL-6, IL-12 LEVELS</title><p>Serum levels of cytokines TNF-<italic>&#x003b1;</italic> IL-6, IL-12 were measured by immunoenzymatic ELISA method (Quantikine High Sensitivity Human by R&#x00026;D Systems, Minneapolis, Minn., USA) according to manufacturer protocol. Minimum detectable concentrations were determined by the manufacturer as 0.12 pg/ml, 0.03 pg/ml, and 1.0 pg/ml, respectively. Intra-assay (2.6 for TNF-<italic>&#x003b1;</italic>; 1.6 for IL-6; 1.1 for IL-12) and interassay (7.4 for TNF-<italic>&#x003b1;</italic>; 6.4 for IL-6; 7.1 for IL-12) precision performances of the assays were determined on 20 replicates from the quality control data of the laboratory.</p></sec><sec sec-type="section" id="sec7"><title>7. STATISTICAL ANALYSIS</title><p>The results were analyzed using The Statistical Version 7.0 program (StatSoft Polska ). The Shapiro-Wilk test was used to evaluate normality of variables. The differences between the groups were calculated with Student <italic>t</italic> or the nonparametric <italic>U</italic>-Mann-Whitney tests.</p><p>A logistic forward regression analysis was used to assess the association between all clinical and inflammatory parameters and retinopathy with a <italic>P</italic> &#x0003c; .05 for entry. Risk for retinopathy was estimated by odds ratios (ORs) with 95% confidence intervals (CIs).</p><p>The &#x003c7;<sup>2</sup> person test was applied for calculating differences between numbers of children with and without detectable cytokines in serum. The results of Student <italic>t</italic> test were presented as arithmetic means &#x000b1;SD. The results of the <italic>U</italic>-Mann-Whitney test were presented as median (min-max). In all analyses a two-tailed significance level &#x0003c;.05 was regarded as statistically significant.</p></sec><sec sec-type="section" id="sec8"><title>8. RESULTS</title><p>The NPDR children demonstrated a significantly longer duration of the disease in addition to higher HbA1c, albumin excretion rate, C-reactive protein, as well as systolic blood pressure than those without retinopathy. There were no significant differences between both groups in the serum creatinine and diastolic blood pressure. Moreover, the NPDR children demonstrated a significantly higher HbA1c, C reactive protein, albumin excretion rate, creatinine in serum, systolic and diastolic blood pressures as compared to the healthy group (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>The serum levels of TNF-<italic>&#x003b1;</italic> and IL-6 in the group with NPDR were significantly higher as compared with children without retinopathy. On the other hand, the IL-12 levels were higher in the NPDR group with regard to the patients without retinopathy, however the difference was statistically insignificant. Children without retinopathy were characterized by significantly higher TNF-<italic>&#x003b1;</italic>, IL-6, as well as IL-12 serum levels in relation to the healthy controls (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>As many as 76% of the NPDR children had a detectable serum level of TNF-<italic>&#x003b1;</italic> while in the group without retinopathy only 34% were TNF-<italic>&#x003b1;</italic> positive. This stands in clear contrast to the healthy group which was absolutely (100%) negative with respect to serum TNF-<italic>&#x003b1;</italic>. The differences between children with and without NPDR were statistically significant. However, all the NPDR children (100%) had a detectable serum level of IL-6 and 70% of children without retinopathy were IL-6 positive. The differences between both diabetic groups were statistically significant. In the healthy group only 2.85% were IL-6 positive. There were no differences between percentages of the IL-12 positive children in the groups with NPDR and without retinopathy, 43% and 24%, respectively.</p><p>Results of the factors predisposing to diabetic retinopathy development in DM1 children are summarized in <xref ref-type="table" rid="T3">Table 3</xref>.</p></sec><sec sec-type="section" id="sec9"><title>9. DISCUSSION</title><p>We have examined a group of 111 children diagnosed with DM type 1, including 21 (26%) children with recognised nonproliferative diabetic retinopathy. In relation to those without retinopathy, the NPDR children demonstrated significantly longer duration of the disease, they had higher HbA1c, urine albumin excretion rate, CRP level, as well as the systolic blood pressure. TNF-<italic>&#x003b1;</italic> was detectable in 76% of the NPDR children and only in 34% of the DM type 1 children without retinopathy. Statistical analysis disclosed TNF-<italic>&#x003b1;</italic> as the only independent early marker indicating occurrence of changes at the fundus of the eye.</p><p>In a few studies published in recent years authors reported detectable TNF-<italic>&#x003b1;</italic> in the serum of children with long-standing diabetes, however these patients had no concomitant diabetic complications [<xref ref-type="bibr" rid="B16">16</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>]. The Chinese scientists analyzed a group of children of less than 5 years of diabetes mellitus type 1 duration having no late complications of the disease [<xref ref-type="bibr" rid="B17">17</xref>]. They showed that TNF-<italic>&#x003b1;</italic> serum levels did not differ from those of the healthy children. The Italian group reported results of a study in which TNF-<italic>&#x003b1;</italic> and IL-6 serum levels were compared between the groups of children being less than one year or over five years from the DM type 1 diagnosis and healthy controls. Children being less than one year form the disease diagnosis presented higher TNF-<italic>&#x003b1;</italic> serum levels in comparison to the other two groups [<xref ref-type="bibr" rid="B18">18</xref>]. On the other hand a different group reported that TNF-<italic>&#x003b1;</italic> serum level was found lower than in the healthy controls [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>The mechanism of TNF-<italic>&#x003b1;</italic> contribution to diabetic retinopathy is not fully elucidated. It has been suggested that hyperglycaemia may lead to the activation of proinflammatory cytokines that are crucial for micro- and macroangiopathy developments [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. In diabetic patients an increased synthesis of the macrophage's RAGE receptors, which bind final glycation products, has been noted [<xref ref-type="bibr" rid="B10">10</xref>]. The RAGE receptors signalize the proinflammatory cytokines' cascade induction, including TNF-<italic>&#x003b1;</italic>, IL-6, and IL-12 [<xref ref-type="bibr" rid="B9">9</xref>&#x02013;<xref ref-type="bibr" rid="B11">11</xref>]. These cytokines may mediate the synthesis of acute phase proteins which are able to initiate and support inflammatory process in the vascular wall. As a consequence, an increased expression of intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) on endothelial cells is induced, which serves as chemoattractants for monocytes and other inflammatory cells [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B20">20</xref>].</p><p>In our study serum IL-6 level was more elevated in NDPR group than without retinopathy children and similar relations concerned the IL-6 positive sera in these groups. On the other hand, IL-6 did not reach a status of an independent retinopathy risk factor. The negative role of IL-6 is also associated with its effect on endothelial dysfunction with an increased permeability and enhanced expression of adhesion molecules on these cells [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>]. Elevated levels of IL-6 both in serum and in vitreous fluid have been detected in proliferative retinopathy in adult patients [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. However, there was no report published in the available literature on the role of IL-6 at the early stages of the diabetic retinopathy development in DM type 1 children. The NPDR children, apart from elevated TNF-<italic>&#x003b1;</italic> and IL-6 levels, did not differ in the IL-12 concentration. Formerly, the role of IL-12 as a proinflammatory cytokine in the insulin-dependent diabetes pathogenesis was shown using the NOD model [<xref ref-type="bibr" rid="B12">12</xref>] and in some limited studies in humans [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>]. Winkler et al. showed that IL-12 may also contribute to the pathogenesis of diabetic retinopathy more likely as a part of the consecutive immunological response mechanisms rather than a predisposing factor [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>On the account of the presented data it appears that, among the analyzed parameters, TNF-<italic>&#x003b1;</italic> is the most significant predictor of damage to the eye apparatus. The early introduction of the TNF-<italic>&#x003b1;</italic> antagonists to the treatment of young patients with DM type 1 who show high serum activity of the cytokine may prevent development of diabetic retinopathy.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This paper was presented during the 16th European Congress of Immunology in Paris, France, 2006. This work was supported by the Medical University of Gda&#x00144;sk, Poland (ST-28, ST-8, and ST-56).</p></ack><glossary><title>ABBREVIATIONS</title><def-list id="DL1"><def-item><term>DM:</term><def><p>Diabetes mellitus</p></def></def-item><def-item><term>NPDR:</term><def><p>Nonproliferative diabetic retinopathy</p></def></def-item><def-item><term>TNF-<italic>&#x003b1;</italic>:</term><def><p>Tumor necrosis factor-alpha</p></def></def-item><def-item><term>IL-6:</term><def><p>Interleukin-6</p></def></def-item><def-item><term>IL:</term><def><p>Interleukin-12</p></def></def-item><def-item><term>ABPM:</term><def><p>Ambulatory blood pressure monitoring</p></def></def-item><def-item><term>RAGE:</term><def><p>Receptor for advanced glycation end product</p></def></def-item><def-item><term>ICAM-1:</term><def><p>Intercellular adhesion molecule-1</p></def></def-item><def-item><term>VCAM-1:</term><def><p>Vascular adhesion molecule-1</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schram</surname><given-names>MT</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name><name><surname>Schalkwijk</surname><given-names>C</given-names></name><etal/></person-group><article-title>Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study</article-title><source><italic>Diabetes Care</italic></source><year>2003</year><volume>26</volume><issue>7</issue><fpage>2165</fpage><lpage>2173</lpage><pub-id pub-id-type="pmid">12832330</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giorgino</surname><given-names>F</given-names></name><name><surname>Laviola</surname><given-names>L</given-names></name><name><surname>Cavallo Perin</surname><given-names>P</given-names></name><name><surname>Solnica</surname><given-names>B</given-names></name><name><surname>Fuller</surname><given-names>J</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name></person-group><article-title>Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study</article-title><source><italic>Diabetologia</italic></source><year>2004</year><volume>47</volume><issue>6</issue><fpage>1020</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">15170497</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lund-Andersen</surname><given-names>H</given-names></name></person-group><article-title>Mechanisms for monitoring changes in retinal status following therapeutic intervention in diabetic retinopathy</article-title><source><italic>Survey of Ophthalmology</italic></source><year>2002</year><volume>47</volume><issue>supplement 2</issue><fpage>S270</fpage><lpage>S277</lpage><pub-id pub-id-type="pmid">12507629</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>KE</given-names></name><name><surname>Neumaier-Ammerer</surname><given-names>B</given-names></name><name><surname>Stolba</surname><given-names>U</given-names></name><name><surname>Binder</surname><given-names>S</given-names></name></person-group><article-title>Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA<sub>1c</sub>)</article-title><source><italic>Graefe's Archive for Clinical and Experimental Ophthalmology</italic></source><year>2006</year><volume>244</volume><issue>11</issue><fpage>1446</fpage><lpage>1452</lpage></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abu el Asrar</surname><given-names>AM</given-names></name><name><surname>Maimone</surname><given-names>D</given-names></name><name><surname>Morse</surname><given-names>PH</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Reder</surname><given-names>AT</given-names></name></person-group><article-title>Cytokines in the vitreous of patients with proliferative diabetic retinopathy</article-title><source><italic>American Journal of Ophthalmology</italic></source><year>1992</year><volume>114</volume><issue>6</issue><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">1463043</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Tamai</surname><given-names>M</given-names></name></person-group><article-title>Quantitative analysis of interleukin-6 in vitreous from patients with proliferative vitreoretinal diseases</article-title><source><italic>Japanese Journal of Ophthalmology</italic></source><year>2001</year><volume>45</volume><issue>1</issue><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">11163044</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuuki</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy</article-title><source><italic>Journal of Diabetes and Its Complications</italic></source><year>2001</year><volume>15</volume><issue>5</issue><fpage>257</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">11522500</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doganay</surname><given-names>S</given-names></name><name><surname>Evereklioglu</surname><given-names>C</given-names></name><name><surname>Er</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comparison of serum NO, TNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus</article-title><source><italic>Eye</italic></source><year>2002</year><volume>16</volume><issue>2</issue><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">11988817</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarter</surname><given-names>RJ</given-names></name><name><surname>Hempe</surname><given-names>JM</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Chalew</surname><given-names>SA</given-names></name></person-group><article-title>Biological variation in HbA<sub>1c</sub> predicts risk of retinopathy and nephropathy in type 1 diabetes</article-title><source><italic>Diabetes Care</italic></source><year>2004</year><volume>27</volume><issue>6</issue><fpage>1259</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">15161772</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokoi</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>S-I</given-names></name><name><surname>Takeuchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy</article-title><source><italic>British Journal of Ophthalmology</italic></source><year>2005</year><volume>89</volume><issue>6</issue><fpage>673</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">15923499</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Shikata</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>J</given-names></name><name><surname>Horiuchi</surname><given-names>S</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name></person-group><article-title>Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-<italic>&#x003b1;</italic> and inducible nitric oxide synthase in diabetic rat glomeruli</article-title><source><italic>Diabetologia</italic></source><year>1999</year><volume>42</volume><issue>7</issue><fpage>878</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">10440132</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothe</surname><given-names>H</given-names></name><name><surname>Burkart</surname><given-names>V</given-names></name><name><surname>Faust</surname><given-names>A</given-names></name><name><surname>Kolb</surname><given-names>H</given-names></name></person-group><article-title>Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice</article-title><source><italic>Diabetologia</italic></source><year>1996</year><volume>39</volume><issue>1</issue><fpage>119</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">8720612</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>American Diabetes Association</surname></name></person-group><article-title>Report of the expert committee on the diagnosis and classification of diabetes mellitus</article-title><source><italic>Diabetes Care</italic></source><year>1997</year><volume>20</volume><issue>7</issue><fpage>1183</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">9203460</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>American Diabetes Association</surname></name></person-group><article-title>Follow-up report on the diagnosis of diabetes mellitus</article-title><source><italic>Diabetes Care</italic></source><year>2003</year><volume>26</volume><issue>11</issue><fpage>3160</fpage><lpage>3167</lpage><pub-id pub-id-type="pmid">14578255</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Early Treatment Diabetic Retinopathy Study Rerearch Group</surname></name></person-group><article-title>Classification of diabetic retinopathy from fluorescein angiograms: ETDRS report number 11</article-title><source><italic>Ophthalmology</italic></source><year>1991</year><volume>98</volume><issue>supplement 5</issue><fpage>807</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">2062514</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>Y</given-names></name><name><surname>Akarsu</surname><given-names>S</given-names></name><name><surname>Ustundag</surname><given-names>B</given-names></name><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Gurgoze</surname><given-names>MK</given-names></name></person-group><article-title>Serum IL-1<italic>&#x003b2;</italic>, IL-2, and IL-6 in insulin-dependent diabetic children</article-title><source><italic>Mediators of Inflammation</italic></source><year>2006</year><volume>2006</volume><fpage>6 pages</fpage><comment>Article ID 59206.</comment></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>H-C</given-names></name><name><surname>Lin</surname><given-names>S-C</given-names></name><name><surname>Wang</surname><given-names>Y-M</given-names></name></person-group><article-title>The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus</article-title><source><italic>Clinical Biochemistry</italic></source><year>2004</year><volume>37</volume><issue>8</issue><fpage>666</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">15302608</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Pomilio</surname><given-names>M</given-names></name><name><surname>Vigneri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Endothelial perturbation in children and adolescents with type 1 diabetes</article-title><source><italic>Diabetes Care</italic></source><year>2001</year><volume>24</volume><issue>9</issue><fpage>1674</fpage><lpage>1678</lpage><pub-id pub-id-type="pmid">11522718</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorini</surname><given-names>R</given-names></name><name><surname>de Amici</surname><given-names>M</given-names></name><name><surname>d'Annunzio</surname><given-names>G</given-names></name><name><surname>Vitali</surname><given-names>L</given-names></name><name><surname>Scaramuzza</surname><given-names>A</given-names></name></person-group><article-title>Low serum levels of tumor necrosis factor-<italic>&#x003b1;</italic> in insulin-dependent diabetic children</article-title><source><italic>Hormone Research</italic></source><year>1995</year><volume>43</volume><issue>5</issue><fpage>206</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">7782051</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balasubramanyam</surname><given-names>M</given-names></name><name><surname>Rema</surname><given-names>M</given-names></name><name><surname>Premanand</surname><given-names>C</given-names></name></person-group><article-title>Biochemical and molecular mechanisms of diabetic retinopathy</article-title><source><italic>Current Science</italic></source><year>2002</year><volume>83</volume><issue>12</issue><fpage>1506</fpage><lpage>1514</lpage></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szmitko</surname><given-names>PE</given-names></name><name><surname>Wang</surname><given-names>C-H</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>de Almeida</surname><given-names>JR</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name></person-group><article-title>New markers of inflammation and endothelial cell activation&#x02014;part I</article-title><source><italic>Circulation</italic></source><year>2003</year><volume>108</volume><issue>16</issue><fpage>1917</fpage><lpage>1923</lpage><pub-id pub-id-type="pmid">14568885</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulseng</surname><given-names>B</given-names></name><name><surname>Vatten</surname><given-names>L</given-names></name><name><surname>Espevik</surname><given-names>T</given-names></name></person-group><article-title>Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: relations to duration and complications of disease</article-title><source><italic>Acta Diabetologica</italic></source><year>1999</year><volume>36</volume><issue>1-2</issue><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">10436260</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Funatsu</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Noma</surname><given-names>H</given-names></name><name><surname>Mimura</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name></person-group><article-title>Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema</article-title><source><italic>American Journal of Ophthalmology</italic></source><year>2002</year><volume>133</volume><issue>1</issue><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">11755841</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Funatsu</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name></person-group><article-title>Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema</article-title><source><italic>Japanese Journal of Ophthalmology</italic></source><year>2002</year><volume>46</volume><issue>1</issue><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11853719</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x00142;owacka</surname><given-names>E</given-names></name><name><surname>Banasik</surname><given-names>M</given-names></name><name><surname>Lewkowicz</surname><given-names>P</given-names></name><name><surname>Tch&#x000f3;rzewski</surname><given-names>H</given-names></name></person-group><article-title>The effect of LPS on neutrophils from patients with high risk of type 1 diabetes mellitus in relation to IL-8, IL-10 and IL-12 production and apoptosis <italic>in vitro</italic></article-title><source><italic>Scandinavian Journal of Immunology</italic></source><year>2002</year><volume>55</volume><issue>2</issue><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">11896938</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>G</given-names></name><name><surname>Dworak</surname><given-names>O</given-names></name><name><surname>Salamon</surname><given-names>F</given-names></name><name><surname>Salamon</surname><given-names>D</given-names></name><name><surname>Speer</surname><given-names>G</given-names></name><name><surname>Cseh</surname><given-names>K</given-names></name></person-group><article-title>Increased interleukin-12 plasma concentrations in both, insulin-dependent and non-insulin-dependent diabetes mellitus</article-title><source><italic>Diabetologia</italic></source><year>1998</year><volume>41</volume><issue>4</issue><fpage>488</fpage><pub-id pub-id-type="pmid">9562356</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical parameters of the DM type 1 children and healthy group. Values are presented as means &#x000b1; SD.</p></caption><table><tbody><tr><td rowspan="1" colspan="1">Clinical parameters</td><td align="center" rowspan="1" colspan="1">Children with NPDR</td><td align="center" rowspan="1" colspan="1">Children without retinopathy</td><td align="center" rowspan="1" colspan="1">Healthy group</td><td align="center" rowspan="1" colspan="1">Statistical significance</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Number of children</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="2" colspan="1">Age (years)</td><td align="center" rowspan="2" colspan="1">15 &#x000b1; 2</td><td align="center" rowspan="2" colspan="1">14 &#x000b1; 3</td><td align="center" rowspan="2" colspan="1">14 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="2" colspan="1">Duration of DM (years)</td><td align="center" rowspan="2" colspan="1">9 &#x000b1; 4</td><td align="center" rowspan="2" colspan="1">5 &#x000b1; 3</td><td align="center" rowspan="2" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr><tr><td rowspan="2" colspan="1">HbA1c (%)</td><td align="center" rowspan="2" colspan="1">9.7 &#x000b1; 1.8</td><td align="center" rowspan="2" colspan="1">8.2 &#x000b1; 1.7</td><td align="center" rowspan="2" colspan="1">4.2 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr><tr><td rowspan="2" colspan="1">C-reactive protein (mg/L)</td><td align="center" rowspan="2" colspan="1">2.3 &#x000b1; 1.0</td><td align="center" rowspan="2" colspan="1">1.4 &#x000b1; 0.8</td><td align="center" rowspan="2" colspan="1">0.3 &#x000b1; 0.04</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr><tr><td rowspan="2" colspan="1">Albumin excretion rate (mg/24)</td><td align="center" rowspan="2" colspan="1">34 &#x000b1; 21</td><td align="center" rowspan="2" colspan="1">18 &#x000b1; 12</td><td align="center" rowspan="2" colspan="1">3 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr><tr><td rowspan="2" colspan="1">Creatinine in serum (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="2" colspan="1">0.9 &#x000b1; 0.9</td><td align="center" rowspan="2" colspan="1">0.9 &#x000b1; 0.8</td><td align="center" rowspan="2" colspan="1">0.5 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr><tr><td rowspan="2" colspan="1">Systolic blood pressure (mm/Hg)</td><td align="center" rowspan="2" colspan="1">122 &#x000b1; 10</td><td align="center" rowspan="2" colspan="1">155 &#x000b1; 11</td><td align="center" rowspan="2" colspan="1">110 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr><tr><td rowspan="2" colspan="1">Diastolic blood pressure (mm/Hg)</td><td align="center" rowspan="2" colspan="1">73 &#x000b1; 10</td><td align="center" rowspan="2" colspan="1">70 &#x000b1; 9</td><td align="center" rowspan="2" colspan="1">68 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF2">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>*Differences between children with nonproliferative retinopathy and without retinopathy.</p></fn><fn id="TF2"><p>**Differences between children with nonproliferative retinopathy and healthy group.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Circulating levels of cytokines in serum of DM type 1 children and healthy group. Values are presented as means &#x000b1; SD.</p></caption><table><tbody><tr><td rowspan="1" colspan="1">Level cytokines</td><td align="center" rowspan="1" colspan="1">Children with NPDR</td><td align="center" rowspan="1" colspan="1">Children without retinopathy</td><td align="center" rowspan="1" colspan="1">Healthy group</td><td align="center" rowspan="1" colspan="1">Statistical significance</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" colspan="1">TNF-<italic>&#x003b1;</italic> (pg/mL)</td><td align="center" rowspan="2" colspan="1">1.7 &#x000b1; 1.4</td><td align="center" rowspan="2" colspan="1">0.6 &#x000b1; 0.8</td><td align="center" rowspan="2" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF3">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF4">**</xref></td></tr><tr><td rowspan="2" colspan="1">IL-6 (pg/mL)</td><td align="center" rowspan="2" colspan="1">3.9 &#x000b1; 1.2</td><td align="center" rowspan="2" colspan="1">1.8 &#x000b1; 0.9</td><td align="center" rowspan="2" colspan="1">0.5 &#x000b1; 0</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF3">*</xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF4">**</xref></td></tr><tr><td rowspan="2" colspan="1">IL-12 (pg/mL)</td><td align="center" rowspan="2" colspan="1">1.8 &#x000b1; 1.6</td><td align="center" rowspan="2" colspan="1">1.2 &#x000b1; 1.5</td><td align="center" rowspan="2" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; .001<xref ref-type="table-fn" rid="TF4">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>*Differences between children with nonproliferative retinopathy and without retinopathy.</p></fn><fn id="TF4"><p>**Differences between children with nonproliferative retinopathy and healthy group.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Unadjusted retinopathy risk gradation.</p></caption><table><tbody><tr><td rowspan="1" colspan="1">Parameters</td><td align="center" rowspan="1" colspan="1">OR</td><td align="center" rowspan="1" colspan="1">95% Cl</td><td align="center" rowspan="1" colspan="1">Statistical significance</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Serum level of TNF-<italic>&#x003b1;</italic> (pg/mL)</td><td align="center" rowspan="1" colspan="1">4.01</td><td align="center" rowspan="1" colspan="1">2.01&#x02013;7.96</td><td align="center" rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">C-reactive protein (mg/L)</td><td align="center" rowspan="1" colspan="1">2.55</td><td align="center" rowspan="1" colspan="1">1.54&#x02013;4.2</td><td align="center" rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">1.58</td><td align="center" rowspan="1" colspan="1">1.22&#x02013;2.06</td><td align="center" rowspan="1" colspan="1">.0004</td></tr><tr><td rowspan="1" colspan="1">Serum level of IL-6 (pg/mL)</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">1.11&#x02013;2.07</td><td align="center" rowspan="1" colspan="1">.007</td></tr><tr><td rowspan="1" colspan="1">Duration of DM (years)</td><td align="center" rowspan="1" colspan="1">1.39</td><td align="center" rowspan="1" colspan="1">1.39&#x02013;1.18</td><td align="center" rowspan="1" colspan="1">.005</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">1.25</td><td align="center" rowspan="1" colspan="1">1.07&#x02013;1.46</td><td align="center" rowspan="1" colspan="1">.003</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure (mm/Hg)</td><td align="center" rowspan="1" colspan="1">1.08</td><td align="center" rowspan="1" colspan="1">1.02&#x02013;1.13</td><td align="center" rowspan="1" colspan="1">.03</td></tr><tr><td rowspan="1" colspan="1">Albumin excretion rate (mg/24)</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">1.00&#x02013;1.03</td><td align="center" rowspan="1" colspan="1">.03</td></tr><tr><td rowspan="2" colspan="1">Diastolic blood pressure (mm/Hg)</td><td align="center" rowspan="2" colspan="1">1.03</td><td align="center" rowspan="2" colspan="1">0.98&#x02013;1.08</td><td align="center" rowspan="1" colspan="1">.2</td></tr><tr><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="2" colspan="1">Creatinine in serum (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="2" colspan="1">1.0</td><td align="center" rowspan="2" colspan="1">0.9&#x02013;1.0</td><td align="center" rowspan="1" colspan="1">.3</td></tr><tr><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="2" colspan="1">Serum level of IL-12 (pg/mL)</td><td align="center" rowspan="2" colspan="1">0.9</td><td align="center" rowspan="2" colspan="1">0.6&#x02013;1.2</td><td align="center" rowspan="1" colspan="1">.7</td></tr><tr><td align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table></table-wrap></floats-wrap></article> 